![]() |
Open for inclusion |
A phase 1/2 dose escalation safety, pharmacokinetic and efficacy study of multiple intravenous administration of a human monoclonal antibody (SAR6509848) against CD38 in patients with selected CD38+ hematological malignanciesCancer type: Hematological malignancies Phase: I/II Principal Investigator: Anttila Pekka Country: FI Keywords: Finland, Helsinki, SAR6509848 Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/study/NCT01084252 |